IL10 and neoplasm: Further studies found that histone deacetylase 11 (HDAC11) and alarmin high mobility group box 1 (HMGB1) are key negative regulators of IL-10 transcription in MDSCs (Villagra et al., 2009; Parker et al., 2014), indicating a promising therapeutic strategy for enhancing anti-tumor immunity.